Rein Therapeutics (RNTX) investor relations material

Company overview and business model

• Clinical-stage biopharmaceutical company developing therapies for orphan pulmonary and fibrosis indications with limited or no approved treatments.

• Lead candidate LTI-03 targets idiopathic pulmonary fibrosis (IPF); LTI-01 development paused to focus resources on LTI-03.

• RENEW Phase 2 trial for LTI-03 underway, enrolling up to 120 IPF patients across global sites.

• Received orphan drug designation for LTI-03 from the European Medicines Agency in January 2026.

Financial performance and metrics

• As of December 31, 2025, had $3.2 million in cash and a working capital deficit of $1.9 million.

• Pro forma as adjusted capitalization post-offering: $62.9 million, assuming full exercise of the offering at $1.66 per share.

• Net tangible book value per share post-offering would be $0.65, with immediate dilution of $1.01 per share to new investors.

• No product revenues to date; expects continued operating losses until product approval and commercialization.

Use of proceeds and capital allocation

• Net proceeds estimated at approximately $48.1 million (assuming $1.66 per share and full exercise of the over-allotment option).

• Proceeds to be used for working capital, general corporate purposes, and repayment of $5.375 million in unsecured promissory notes.

• Management retains broad discretion over allocation of funds.